These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Matheson AJ; Figgitt DP Drugs; 2001; 61(6):833-65. PubMed ID: 11398914 [TBL] [Abstract][Full Text] [Related]
3. Valdecoxib: a review. Chavez ML; DeKorte CJ Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704 [TBL] [Abstract][Full Text] [Related]
4. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687 [TBL] [Abstract][Full Text] [Related]
5. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215 [TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP; Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224 [TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201 [TBL] [Abstract][Full Text] [Related]
9. The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: a review. Fine PG; J Pain; 2002 Aug; 3(4):272-83. PubMed ID: 14622751 [TBL] [Abstract][Full Text] [Related]
12. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458 [TBL] [Abstract][Full Text] [Related]
13. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Saag K; van der Heijde D; Fisher C; Samara A; DeTora L; Bolognese J; Sperling R; Daniels B Arch Fam Med; 2000; 9(10):1124-34. PubMed ID: 11115219 [TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacology of the selective COX-2 inhibitors]. Burian M; Geisslinger G Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909 [TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Pellissier JM; Straus WL; Watson DJ; Kong SX; Harper SE Clin Ther; 2001 Jul; 23(7):1061-79. PubMed ID: 11519771 [TBL] [Abstract][Full Text] [Related]
18. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Zhao SZ; Wentworth C; Burke TA; Makuch RW Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778 [TBL] [Abstract][Full Text] [Related]
19. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J; Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]